Results 81 to 90 of about 9,019,411 (282)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Multiple synchronous primary malignancies induced by benzene exposure: a case report

Journal of Occupational Medicine and Toxicology, 2009
Background Chronic exposure to high concentrations of benzene is usually associated with the development of haematological diseases. However, solid tumors induced by benzene exposure are less frequent.
Shen Huahao, Zhang Gensheng, Wang Pingli
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis [PDF]

, 2010
Objectives: Prediction of long term clinical outcome in patients with primary progressive multiple sclerosis (PPMS) using imaging has important clinical implications, but remains challenging.
Polman, C., Barkhof, F., Montalban, X, CHARD D, Thompson, A, Polman, C, F. Barkhof, Chard, D, Samson, R., D. Miller, Bodini, B., A. Thompson, Samson, R, MONTALBAN X, R. Samson, Rovira, A, POLMAN C, KHALEELI Z, O. Ciccarelli, Filippi, M., N. De Stefano, Barkhof, F, BATTAGLINI, MARCO, B. Bodini, A. Rovira, Battaglini, M, Polman, C.H., Chard, D., CICCARELLI O., Miller, D., Rovaris, M, Battaglini, M., Thompson, A., De Stefano, N., X. Montalban, MILLER D, ROVARIS M, FILIPPI M, D. Chard, Khaleeli, Z, SAMSON R, ROVIRA A, THOMPSON A, Rovaris, M., De Stefano, N, Rovira, A., Z. Khaleeli, Bodini, B, BODINI B, M. Filippi, Miller, D, BARKHOF F, DE STEFANO, NICOLA, M. Rovaris, Montalban, X., Ciccarelli, O., Ciccarelli, O, Khaleeli, Z., M. Battaglini, C. Polman, Filippi, M, Rovira, Alex, Stefano, N. De, Rovaris, Marco, Thompson, Alan, De Stefano N, Battaglini M, FILIPPI , MASSIMO, Barkhof, Frederik, Polman, Chris, Montalban, Xavier, Ciccarelli, Olga, Miller, David, Filippi, Massimo, Khaleeli, Zhaleh, Chard, Declan, Filippi, M., Bodini, Benedetta, Samson, Rebecca   +78 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Metachronous malignancies in head and neck region: Report of two cases

Indian Journal of Pathology and Microbiology, 2014
The development of a second primary cancer after treatment of the first with radiotherapy or chemotherapy is well documented. Multiple metachronous primary cancers are known to occur in an individual, but it is often seen with hematological malignancies ...
Sushma Yalavarthi, Pramod Kumar Pamu, Mallesh Thoondla, Saloni Gupta   +3 more
doaj   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

A Rare Occurrence of Solid Gynecological Malignancy Synchronous with Hematological Malignancy: Rare Case and Review of Literature

Indian Journal of Medical and Paediatric Oncology
A synchronous solid and hematological malignancy is an uncommon condition in which a patient develops two or more primary cancers, one of which is a solid malignancy and the other one is a hematological malignancy, within 6 months of primary cancer ...
Rubi Gupta, Pariseema Dave, Bijal Patel, Remi Abdul Shukur   +3 more
doaj   +1 more source

Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study [PDF]

, 2015
Immunodeficiency is associated with higher cancer incidence. However, it is unknown whether there is a link between immunodeficiency and development of multiple primary malignancies.
DODARO, CONCETTA ANNA, C. Dodaro, RICCIO, ELEONORA, FEDERICO, STEFANO, SANTANGELO, MICHELE, M. L. Santangelo, E. Riccio, CARLOMAGNO, NICOLA, V. Tammaro, A. Pisani, CRISCITIELLO, CARMEN, N. Carlomagno, G. Curigliano, PISANI, ANTONIO, Giuseppe Curigliano, SCOTTI, ALESSANDRO, C. Criscitiello, TAMMARO, VINCENZO, RENDA, ANDREA, CALOGERO, ARMANDO, A. Scotti, A. Calogero, A. Renda, S. Federico   +23 more
core   +1 more source